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Although bacterial endotoxin, such as lipopolysac-
charide (LPS), plays a key role in the pathogenesis
of nonalcoholic steatohepatitis (NASH), detailed
mechanisms of this pathogenesis remain unclear.
Here, we demonstrate that upregulation of CD14 by
leptin-mediated signaling is critical to hyperreactivity
against endotoxin during NASH progression. Upre-
gulation of CD14 in Kupffer cells and hyperreactivity
against low-dose LPS were observed in high-fat diet
(HFD)-induced steatosis mice, but not chow-fed-
control mice. Hyperresponsivity against low-dose
LPS led to accelerated NASH progression, including
liver inflammation and fibrosis. Administering leptin
in chow-fed mice caused increased hepatic expres-
sion of CD14 via STAT3 signaling, resulting in hyper-
reactivity against low-dose LPS without steatosis. In
contrast, amarked decrease in hepatic CD14 expres-
sion was observed in leptin-deficient ob/ob mice,
despite severe steatosis. Our results indicate that
obesity-induced leptin plays a crucial role in NASH
progression via enhanced responsivity to endotoxin,
and we propose a mechanism of bacteria-mediated
progression of NASH.
INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) is an important cause of
chronic liver injury in many countries (Angulo, 2002; Clark et al.,
2002; Marchesini et al., 2003; Neuschwander-Tetri andCaldwell,
2003; Sanyal, 2002). Data collected from the United States have
shown that the prevalence of NAFLD has increased steadily in
recent years, despite other diseases remaining at steady states
(Younossi et al., 2011). NAFLD ranges from benign simple stea-
tosis to steatohepatitis (including nonalcoholic steatohepatitis,44 Cell Metabolism 16, 44–54, July 3, 2012 ª2012 Elsevier Inc.NASH); this latter condition includes progressive fibrosis (Day,
2002; Fan et al., 2007) and hepatocellular carcinoma (Day and
Saksena, 2002; Harrison et al., 2003; Powell et al., 1990). As
the probability of developing advanced fibrosis and hepatocel-
lular carcinoma is significantly greater in individuals with steato-
hepatitis than in those with simple steatosis, it is important to
elucidate the mechanism underlying the progression from stea-
tosis to steatohepatitis.
Obesity is strongly associated with NASH pathogenesis,
largely related to changes in the serum concentration of several
important adipokines. One such adipokine is the 16 kDa protein
hormone leptin. Leptin is known to play a pivotal role in energy
homeostasis due to its activity upon certain neurons (Je´quier,
2002). In addition, it has been reported that leptin promotes
insulin resistance and the activation of the transforming growth
factor beta signaling pathway, resulting in the development of
hepatic fibrosis via activation of stellate cells (Patel et al.,
2003). However, the direct role of leptin in the pathogenesis of
NASH has yet to be identified.
In addition to obesity, chronic inflammation is an important
contributing factor in NASH pathogenesis (Wellen and Hotami-
sligil, 2005; Xu et al., 2003). As a major outer membrane con-
stituent of gram-negative bacteria, lipopolysaccharide (LPS),
also referred to as endotoxin, is considered a potent inducer
of hepatic inflammation. LPS may be capable of stimulating
inflammation, cytokine production, and accumulation of inflam-
matory cells within the liver. In fact, LPS has been reported to be
the predominant cause of liver neutrophil infiltration in NASH
patients (Chitturi and Farrell, 2001; Zhao et at., 2004). In addi-
tion, several previous reports have shown that gut permeability,
or small intestinal bacterial overgrowth, was observed more
frequently in NASH patients when compared with healthy
controls (Miele et al., 2009; Shanab et al., 2011).
Despite these findings, the impact of increased serum endo-
toxin levels during NASH progression remains controversial.
Namely, it is unclear whether serum endotoxin levels are signifi-
cantly higher in NASH patients than those in control subjects or
patients presenting with simple steatosis. Alison et al. reported
that serum endotoxin levels are elevated in NAFLD patients
Figure 1. Hepatic Responsivity to a Single
Low-Dose of LPS Is Enhanced Following A
HFD in WT Mice
(A) HE-stained paraffin-embedded sections of liver
tissue from saline- or lipopolysaccharide (LPS)-
treated 20-week-old wild-type (WT) mice after
feeding chow or high-fat diet (HFD) for 12 weeks.
Representative images of liver sections obtained
at 6 hr following a single low-dose LPS treatment
(0.25 mg/kg) are shown. Arrowheads indicate
infiltration of inflammatory cells. Scale bar,
100 mm.
(B) Serum alanine aminotransferase (ALT) levels in
LPS-treated WT mice after feeding chow or HFD
for 8, 10, or 12 weeks (n=5 per group). Sera were
collected 6 hr after LPS treatment.
(C) Relative expression levels of hepatic Toll like
receptor 4 (TLR4), tumor necrosis factor alpha
(TNFa), and Interleukin-6 (IL-6) mRNA in LPS-
treated WT mice after feeding chow or HFD for 8,
10, or 12 weeks (n=5 per group). We show the
maximum levels of these mRNA after the LPS
treatment (pretreatment or 1.5, 3, 6, and 12 hr after
the LPS treatment). mRNA expression levels are
calculated as the ratio relative to those in chow-fed
WT mice for 8 weeks without the LPS treatment
(pre-LPS treatment, 0 hr). Results are presented as
means ± SD. Statistical significance was deter-
mined using Student’s t-test (*p value < 0.05,
**p value < 0.01).
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Loguercio et al. showed that endotoxemia is absent in all NAFLD
patients (Loguercio et al., 2004).
At present, there is general agreement that mild portal endo-
toxemia can be detected in healthy subjects due to gut-derived
bacterial endotoxin (Triger et al., 1978). However, the levels of
such portal endotoxemia observed under healthy conditions
do not usually cause liver dysfunction (Jacob et al., 1977). We
therefore propose that it may be necessary to consider a low-
level endotoxin-mediated mechanism for the progression of
NASH. Here we have investigated new mechanisms involved
in obesity and leptin for NASH progression. Specifically, we
hypothesized that an obesity-mediated increase in leptin levels
induces hyperreactivity against low-level endotoxin, resulting
in NASH progression. We show here direct evidence that
obesity-induced leptin plays a crucial role in the progression of
NASH by regulating the hepatic inflammatory response to endo-
toxin, and propose a bacteria-mediated pathogenesis of NASH.
RESULTS
A High-Fat Diet Enhances Low-Dose LPS-Induced Liver
Injury via an Increase in the Expression of TLR4 and
Proinflammatory Cytokines
Male C57BL/6J mice (8 weeks old) were fed either a normal
chow (chow) or high-fat diet (HFD) for 8, 10, or 12 weeks (Fig-
ure S1A). Characteristics of these mice are shown in Table S1.
During this period, HFD-fed mice presented simple steatosis
without liver fibrosis. To investigate responsivity against low-
level endotoxin, we intraperitoneally injected chow- or HFD-fed
(for 8, 10, or 12 weeks) mice with vehicle (saline) or E. coli-derived LPS (Figure S1A). An LPS dose of 0.25 mg/kg was
chosen for subsequent experiments because this was the
highest dose that did not significantly alter serum ALT levels in
chow-fed mice for 12 weeks (Figure S1B). In addition, we inves-
tigated the plasma levels of endogenous LPS or LPS following
LPS treatment in chow- and HFD-fed (12 weeks) mice (Fig-
ure S1A). The plasma levels of endogenous LPS or LPS following
LPS treatment were not increased in HFD-fed mice compared
with those of chow-fed mice (Figure S1C). These results indicate
that there is no difference between chow and HFD-fed mice in
the direct effects of endogenous LPS or LPS following LPS
treatment.
An increase in the infiltration of inflammatory cells was
observed in the liver of HFD-fed (12 weeks) mice after a single
treatment with low-dose LPS (0.25 mg/kg, Figure 1A). In
contrast, infiltration of inflammatory cells was not observed in
the liver of chow-fed mice, despite treatment with the same
dose of LPS (Figure 1A). Low-dose LPS treatment also led to
a significant increase in serum ALT levels in 10 and 12 weeks-
HFD-fed mice, but not in 8 weeks-HFD- or chow-fed mice (Fig-
ure 1B). Serum ALT levels were not elevated by treatment with
saline in either chow- or HFD-fed mice (Figure S1D). As shown
in Figure 1C, the mRNA expression levels of Toll like receptor 4
(TLR4) and proinflammatory cytokines, such as tumor necrosis
factor alpha (TNFa) and interleikin-6 (IL-6), increased in HFD-
fed (10 and 12 weeks) mice after a single treatment of low-
dose LPS compared with those in chow-fed mice. This increase
in mRNA was not observed after treatment with saline in both
chow- and HFD-fed mice (data not shown). These results indi-
cate that HFD-mediated obesity is a key causative step in the
inflammatory response against low levels of endotoxin, resultingCell Metabolism 16, 44–54, July 3, 2012 ª2012 Elsevier Inc. 45
Figure 2. Hepatic Inflammation and Fibrosis Are
Significantly Progressed in HFD Mice After Long-
Term, Low-Dose LPS Treatment, whereas Limited
Inflammation and No Fibrosis Are Observed in the
Liver of LPS-Treated Chow-Fed Mice
(A–E) Mice were sacrificed 1.5 hr after the last lipopoly-
saccharide (LPS) treatment. (A) HE-stained paraffin-
embedded sections of liver tissue from saline- or LPS-
treated 20-week-old wild-type (WT) mice fed chow or
high-fat diet (HFD) for 12 weeks. Scale bar, 200 mm.
Arrowheads indicate infiltration of inflammatory cells.
NAFLD activity score (NAS score) of each treatment group
is shown (n=6 per group). (B) Serum alanine aminotrans-
ferase (ALT) levels and relative expression levels of
hepatic Toll like receptor 4 (TLR4), tumor necrosis factor
alpha (TNFa), and Interleukin-6 (IL-6) mRNA in saline- or
LPS-treated chow- or HFD-fed mice (n=6 per group). (C)
Masson and tricrome (MT)-stained paraffin-embedded
sections of liver tissue from saline- or LPS-treated chow- or
HFD-fed mice. Arrowheads indicate extended fibrosis.
Scale bar, 100 mm. (D) Fibrotic area in the liver of saline- or
LPS-treated chow- or HFD-fed mice (n=6 per group). (E)
Relative expression levels of hepatic collagen 1a1 and
alpha smooth muscle actin (a-SMA) mRNA in LPS-treated
chow- or HFD-fed mice (n=6 per group). Results are
presented as means ± SD. Statistical significance was
determined using ANOVA with Scheffe’s multiple testing
correction. (*p value < 0.05, **p value < 0.01).
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serum ALT.
Chronic Exposure to Low-Dose LPS with HFD Leads to
Liver Inflammation and Fibrosis
Next, we investigated the effects of chronic low-level endotoxin
exposure on hepatic inflammation in HFD-fedmice for 12 weeks.
Intraperitoneal injections of low-dose LPS (0.25 mg/kg) were
given daily for 4 weeks to chow- and HFD-fed mice (Figure S2A).
This dose of LPS did not significantly alter body weight (Fig-
ureS2B) or affectmousemortality (data not shown). Interestingly,
increased liver weight, hepatic triglyceride (TG) content, and46 Cell Metabolism 16, 44–54, July 3, 2012 ª2012 Elsevier Inc.serum ALT levels were observed in HFD-fed
mice after chronic exposure to low-level LPS,
whereas no difference was observed in chow-
fed mice (Table S2). Subsequent liver histology
showed a marked increase in infiltration of
inflammatory cells in the liver of the LPS-treated
HFD-fed mice when compared with that in
chow-fed mice (Figure 2A). This resulted in an
increased NAFLD activity score (NAS) in HFD-
fed mice, but not in chow-fed mice (Figure 2A).
As shown in Figure 2B, serum ALT levels were
significantly increased in HFD-fed mice after
long-term, low-dose LPS treatment, whereas
no elevation of serum ALT levels was observed
in the LPS-treated chow-fed mice. Although
hepatic TLR4, TNFa, and IL-6 mRNA expression
levels were significantly increased in both chow-
and HFD-fed mice following low-dose LPS
treatment, the levels in HFD-fed mice weresignificantly higher than those in chow-fed mice (Figure 2B).
These results indicate that chronic exposure to low-dose LPS
causesmarkedly increased TLR4, TNFa, and IL-6mRNA expres-
sion in HFD-fed mice, resulting in liver inflammation.
In addition to the observed liver inflammation, hepatic
fibrosis was significantly extended in HFD-fed mice following
long-term, low-dose LPS treatment (Figure 2C). In contrast, no
marked extension of hepatic fibrosis was observed in chow-
fed mice, despite the LPS treatment (Figure 2C). The extent of
fibrosis was confirmed by Sirius red staining (SR staining) and
by collagen 1a1 and a-smooth muscle actin (a-SMA) mRNA
expression, which are closely associated with hepatic fibrosis
Figure 3. A HFD Increases CD14-Positive
Kupffer Cells in WT Mice
(A) Relative expression levels of hepatic CD14
mRNA expression in 20-week-old wild-type (WT)
mice after feeding chow or high-fat diet (HFD) for
up to 12 weeks (n=6 per group).
(B) Protein expression of hepatic CD14 in WT mice
after feeding chow or HFD for 12 weeks (n=5 per
group).
(C) Immunofluorescence of F4/80 (green) and
CD14 (red) in the liver of 20-week-old WT mice
after feeding chow or HFD for 12 weeks (chow-
or HFD-fed mice). Nuclei were stained with 40-
diamidine-20-phenylindole hydrochloride (DAPI;
blue).
(D) Number of F4/80- or CD14-positive cells in the
liver of chow or HFD mice (n=6 per group). mRNA
expression levels are calculated as the ratio rela-
tive to those in 8-week-old WT mice (prefeeding
diet). Results are presented as means ± SD.
Statistical significance was determined using
Student’s t-test (*p value < 0.05, **p value < 0.01).
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dose LPS treatment causes dramatic hepatic fibrosis via
increased hepatic inflammation under HFD-induced steatosis.
CD14-Positive Kupffer Cells Regulate the Hepatic
Inflammatory Response against LPS
To elucidate the mechanism for an enhanced inflammatory
response against low-dose LPS in HFD-induced steatosis, we
investigated factors associated with hepatic LPS signaling in
chow- or HFD-fed mice fed for up to 12 weeks (Figure S3Ai).
HFD-fed mice developed obesity, insulin resistance (IR), liver
dysfunction, and fatty liver compared with chow-fed mice, while
neither hepatic infiltration of inflammatory cells nor hepatic
fibrosis was present in HFD-fed mice, even after 12 weeks (Fig-
ure S3B). We did, however, find upregulated expression of
CD14, which serves as a receptor for complexes of LPS and
LPS-binding protein and regulates responsivity to LPS (Delude
et al., 1995; Wright et al., 1990), in the livers of HFD-fed (8 weeks)
mice by cDNA microarray analysis (Figure S3Aii and Table S3).
We observed time-dependent upregulation of hepatic CD14
mRNA expression by real-time PCR analysis in chow- or HFD-
fed mice (Figure 3A), as well as upregulation of hepatic CD14
protein expression by western blotting in chow- or HFD-fed
mice for 12 weeks (Figure 3B).
To investigate the localization of CD14 expression in the liver,
we performed immunohistochemical staining with anti-CD14
and anti-F4/80 antibodies, as markers for monocyte, macro-Cell Metabolism 16,phage, and Kupffer cell lineages.
Confocal microscopic images showed
that CD14-positive cells were almost
merged with F4/80-positive cells (Figures
3C and S3C). Although the number of F4/
80-positive cells in the liver was essen-
tially unchanged between chow- and
HFD-fed mice (12 weeks), the number of
CD14-positive cells in the liver was signif-
icantly higher in HFD-fedmice than that inchow-fed mice (Figure 3C). However, the total number of CD14-
positive cells was less than that of F4/80 positive cells (Fig-
ure 3D). In contrast, CD14-positive cells were not merged with
a-smooth muscle actin (a-sma)-positive cells, as identified stel-
late cells, and DEC-205-positive cells, as identified dendritic
cells, and CD146-positive cells, as identified sinusoidal endothe-
lial cells (Figure S3D).
Here, we investigated the effects of pretreatment with the
Kupffer cells blocker, gadolinium chloride (GdCl3), to confirm
that CD14 is mainly expressed in Kupffer cells (Figure S3Aiii).
The blockage of Kupffer cells by GdCl3 induced a decrease in
hepatic F4/80 and CD14 expression (Figure S3E). These results
indicate that HFD leads to an increase in hepatic CD14-positive
cells, which are likely to be Kupffer cells.
Next, we investigated the role of CD14-positive Kupffer cells
on increased responsivity against LPS in the liver by silencing
hepatic CD14 with RNA interference (RNAi) and blocking Kupffer
cells using GdCl3 in mice following a 12-week HFD (Figure S4A).
Hepatic CD14 mRNA expression levels and the number of
CD14-positive Kupffer cells in HFD-fed mice were reduced
following CD14 silencingwith siRNA to the same degree as those
in the chow-fedmice (Figures 4A and 4B). Furthermore, silencing
CD14 with siRNA in HFD fed-mice significantly inhibited the
increase in serum ALT levels induced by a single low- dose of
LPS as well as the blockage of Kupffer cells by GdCl3 (Figures
4C and S4B). In addition, silencing CD14 with siRNA in HFD
fed-mice significantly inhibited the increase in hepatic TLR4,44–54, July 3, 2012 ª2012 Elsevier Inc. 47
Figure 4. Silencing Hepatic CD14 Expression Led to a Decreased Responsivity to Low-Dose LPS in the Livers of HFD-Fed Mice to the Same
Degree as Chow-Fed Mice
(A–C) We investigated the effects of CD14 small interfering RNA (siRNA) compared with those of control siRNA. (A) Relative expression levels of CD14 mRNA in
the livers of 20-week-old wild-type (WT) mice fed chow or HFD for 12 weeks (chow- or HFD-fed mice), 24 hr after silencing CD14 with RNA interference (RNAi)
(n=5 per group). (B) Immunofluorescence of F4/80 (green) and CD14 (red) in the livers of HFD-fedmice and the number of F4/80- or CD14-positive cells in the liver
of HFD-fed mice (n=5 per group), 24 hr after silencing CD14 with RNAi. Nuclei were stained with 40- diamidine-20-phenylindole hydrochloride (DAPI; blue). (C)
Serum alanine aminotransferase (ALT) levels and relative expression levels of hepatic Toll like receptor 4 (TLR4), tumor necrosis factor alpha (TNFa), and
Interleukin-6 (IL-6) mRNA in saline- or LPS-treated chow- or HFD-fed mice after silencing CD14 with RNAi (n=5 per group). These mice were intraperitoneally
injected with a saline or a single low-dose LPS treatment (0.25 mg/kg) 24 hr after silencing CD14 with RNAi. These mice were sacrificed at 1.5 hr or 6 hr after
treatment with saline or LPS to investigate hepatic TLR4, TNFa, and IL-6mRNA or serumALT levels. Results are presented asmeans ± SD. Statistical significance
was determined using ANOVA with Scheffe’s multiple testing correction (A) and (C) or Student’s t-test (B) (*p value < 0.05, **p value < 0.01).
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low-dose of LPS to the same degree as those in the LPS-induced
chow-fed mice (Figure 4C). In addition, we confirmed that the
treatment with control or CD14 siRNA did not effect on hepatic
CD14 expression and responsivity to LPS in HFD-fed mice
compared with those in HFD-fed mice with no siRNA (Figures
S4C and S4D). These results indicate that silencing hepatic
CD14 lead to a deterioration of the hyperresponsivity to LPS in
the liver as well as the blockage of Kupffer cells, suggesting
that expression of CD14 in Kupffer cells is important for respon-
sivity to low-dose bacterial endotoxin in the liver.
Leptin Enhances Responsivity against Low-Dose LPS
via Upregulation of Hepatic CD14 through Activation
of STAT3 Signaling
To elucidate whether dietary fat and leptin can directly affect
hepatic CD14 expression, we investigated changes in hepatic48 Cell Metabolism 16, 44–54, July 3, 2012 ª2012 Elsevier Inc.CD14 expression in leptin-deficient ob/ob mice (ob/ob mice)
(Figure S5A1i). Ob/ob mice fed a normal chow without HFDs
present with severe obesity and steatosis. Interestingly, hepatic
CD14 expression was dramatically decreased in ob/ob mice
after a 4-week chow (see chow-fed ob/ob mice in Figure 5A)
in comparison to that in chow-fed wild type (WT) mice. This
change in CD14 expression was exaggerated following HFD
(see HFD on WT vs. HFD on ob/ob mice in Figure 5A).
We also found that supplementary administration of recombi-
nant leptin in ob/ob mice resulted in increased hepatic CD14
expression (Figure 5A). This increased CD14 expression due to
leptin administration was also observed in chow-fed WT mice
(Figure 5A). These findings indicate that leptin signaling may
regulate hepatic CD14 expression. In fact, serum leptin levels of
HFD-fed WT mice were significantly higher than those in chow-
fedWTmice, in parallel with hepatic CD14 expression (Figure 5B;
see chow-fed WT mice vs. HFD-fed WT mice in Figure S5A1i).
Figure 5. Leptin-Induced Hepatic CD14 Expression Enhances Responsivity against Low-Dose LPS through Activation of STAT3 Signaling
(A) Relative expression levels of CD14 mRNA in wild type (WT) or ob/obmice. Chow- or high-fat diet (HFD)-fed WTmice (12 weeks) and chow- or HFD-fed ob/ob
mice (4 weeks), following analysis of their livers (n=5 per group). Relative expression levels of CD14 mRNA in saline- or leptin-treated, chow-fed WT mice and
chow-fed ob/ob mice are indicated (n=4 per group). We investigated their livers 2 hr after leptin treatment.
(B) Serum leptin levels in chow- or HFD-fed WT mice and chow- or HFD-fed ob/ob mice (n=5 per group).
(C) Relative expression levels of hepatic CD14 mRNA and serum leptin levels in 12-week-old db/+ or db/dbmice after feeding chow for 4 weeks (db/+ or db/db
mice).
(D) Immunoblot analysis of Tyr1138-phosphorylated ObRb (p-ObR) and phosphorylated STAT3 (p-STAT3) in the liver of chow- or HFD-fed WT mice.
(E) Immunofluorescence of F4/80 with OBR or p-STAT3 in the liver of chow- or HFD-fed WT mice. Arrows indicate colocalized cells.
(F) Relative expression levels of hepatic CD14 mRNA in HFD-fed WT mice after treatment with saline or STAT3 inhibitor (S31-201). We intraperitoneally injected
a single-dose of STAT3 inhibitor in 200 mL of 5% DMSO (50 mg/body) to HFD-fed WT mice. Mice were sacrificed 4 hr after injection of the STAT3 inhibitor.
(G and H) (G) Serum ALT levels and (H) relative expression levels of hepatic TNFamRNA in saline- or LPS-treated chow-fedWTmice after another saline or leptin
treatment (n=5 per group). We injected a single low-dose LPS to chow-fedWTmice (12 weeks) intraperitoneally 2 hr after leptin administration, and subsequently
sacrificed these mice at 1.5 hr (to evaluate TNFa expression levels) or 6 hr (to evaluate serum ALT levels) after the LPS treatment. Results are presented
as means ± SD. Statistical significance was determined using ANOVA with Scheffe’s multiple testing correction (A), (B), (G) and (H), or Student’s t-test (C) and (F)
(*p value < 0.05, **p value < 0.01).
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expression, we investigated leptin receptor-deficient db/db
mice, which present with severe obesity and steatosis following
normal chow, as well as ob/obmice, (Figure S5A1ii). Importantly,
we found that hepatic CD14 expression in db/db mice was
significantly decreased despite hyperleptinemia in comparison
with that in db/+ mice (Figure 5C). These results suggest that
leptin signaling may be required for increased hepatic CD14
expression.
Leptin induces phosphorylation of Tyr1138 in the long form
of leptin receptor ObRb, resulting in STAT3 activation (Banks
et al., 2000). Immunoblot analysis showed that increased phos-
phorylation of Tyr1138-ObRb (p-ObRb) and STAT3 (p-STAT3)
were observed in the liver of HFD-fed mice compared with
those in chow-fed mice (Figure 5D; see chow-fed WT mice vs.
HFD-fed WT mice in Figure S5A1i). These results indicate
that an obesity-induced increase in leptin can activate ObR-
STAT3 signaling in HFD-fed WT mice compared with chow-fed
WT mice.
To identify which cells were targeted by leptin signaling, we
performed immunohistochemical staining with anti-F4/80, anti-
ObR, and anti-p-STAT3 in the liver of chow- and HFD-fed WT
mice (see chow-fed WT mice vs. HFD-fed WT mice in Fig-
ure S5A1i). Interestingly, confocal microscopy showed that
ObR-positive cells were merged with F4/80-positive cells in the
liver of both chow- and HFD-fedWTmice, and p-STAT3-positive
cells were colocalized with F4/80-positive cells in the liver of
HFD-fed WT mice (Figure 5E). These results indicate that lep-
tin-induced ObR-STAT3 signaling is activated in F4/80-positive
cells, which may be identified as Kupffer cells.
To confirm the role of ObR-STAT3 signaling on hepatic CD14
expression in HFD-fed WT mice, a selective STAT3 inhibitor
(S31-201)was administered toHFD-fedWTmice (FigureS5A1iii).
Our data show that hepatic CD14 expression levels are
decreased in HFD-fed WT mice after the administration of the
STAT3 inhibitor (S31-201; Figure 5F), suggesting that STAT3
signaling is required for leptin-induced upregulation of hepatic
CD14 expression.
To investigate the involvement of leptin in hyperresponsivity
against LPS, we examined serum ALT levels and hepatic TLR4
and TNFa mRNA expression levels in LPS-treated chow-fed
WT mice after exogenous leptin administration (Figure S5A2).
Administration of leptin induced an increase of p-STAT3-positive
cells, colocalized with F4/80-positive cells in the liver of chow-
fed WT mice, as well as that in HFD-fed WT mice (data not
shown). Administration of leptin without LPS did not induce
any increase in serum ALT levels and hepatic TNFa mRNA
expression in chow-fed WTmice; this is in contrast to how these
levels were significantly increased in chow-fed mice by adminis-
tration of leptin with a single low-dose of LPS compared with
those in the LPS-treated chow-fed WT mice without administra-
tion of leptin (Figures 5G and 5H). These results indicate that
leptin enhances responsivity against low-dose bacterial endo-
toxin even under chow-fed conditions, which does not present
with obesity and steatosis.
Next, we examined serum ALT levels and hepatic TNFamRNA
expression levels in LPS-treated chow- or HFD-fed ob/ob mice
with or without exogenous leptin administration to investigate
the involvement of leptin-deficiency in responsivity against LPS50 Cell Metabolism 16, 44–54, July 3, 2012 ª2012 Elsevier Inc.(Figure S5A3). Serum ALT levels were not significantly increased
in chow- or HFD-fed ob/ob mice even though these mice ex-
hibited severe obesity and steatosis, unlike HFD-fed WT mice
after single low-dose LPS treatment (0.25 mg/kg). By contrast,
the administration of leptin increased serum ALT levels in
LPS-treated chow- and HFD-fed ob/ob mice (Figure S5B).
Furthermore, hepatic TNFa mRNA expression was significantly
increased in the LPS-treated chow- or HFD-fed ob/ob mice
following the administration of leptin compared with those in
LPS-treated chow- or HFD-fed ob/ob mice not treated with lep-
tin (Figure S5C; left panel). Interestingly, however, LPS-induced
hepatic TNFamRNA expression was lower in chow- or HFD-fed
ob/obmice than in chow- or HFD-fedWTmice (Figure S5C; right
panel). These results indicate that leptin-deficiency decreased
responsivity against low-dose bacterial endotoxin despite the
mice exhibiting severe obesity and steatosis.
We also investigated the effect of chronic low-level endotoxin
exposure on hepatic fibrosis in chow- or HFD-fed ob/obmice for
4 weeks (Figure S5A4). Intraperitoneal injections of low-dose
LPS (0.25mg/kg) daily for 4weeks did not induce hepatic fibrosis
even in HFD-fed ob/ob mice, unlike HFD-fed WT mice (Fig-
ure S5D). The fibrotic area and hepatic collagen 1a1 and
a-SMA mRNA expression were not increased in ob/ob mice
following LPS treatment, unlike HFD-fed WT mice (Figures S5E
and S5F). These results indicate that long-term, low-dose LPS
treatment did not cause hepatic fibrosis despite the mice exhib-
iting severe obesity and steatosis.
Leptin Induces CD14 Expression in RAW246.7 Cells,
Resulting in Increased LPS-Induced TNFa Production
To assess the effects of leptin and ObR-STAT3 signaling on
CD14 expression in Kupffer cells, we incubated RAW264.7 cells,
the murine monocyte/macrophage cell line, with recombinant
leptin alone or leptin with STAT3 inhibitor (S31-201; Figure S6Ai).
Culture with recombinant leptin dramatically elevated CD14
expression in RAW264.7 cells in a dose-dependent manner,
while the addition of STAT3 inhibitor attenuated this effect
(Figures 6A and 6B). In addition, leptin-inducedCD14 expression
was also significantly elevated in Kupffer cells isolated from
chow-fedWTmicewhen the concentration of recombinant leptin
used was above 10 nM (Figures S6Aii and S6B). We also found
that LPS-induced TNFa production was increased by recombi-
nant leptin with a significant effect at more than 50 nM compared
with LPS alone in RAW264.7 cells, while STAT3 inhibitor attenu-
ated these effects (Figure 6C and Figure S6Aiii). Furthermore,
leptin did not increase TNFa production without LPS (Figure 6C).
These results indicate that leptin and ObR-STAT3 signaling
are required for CD14 expression in Kupffer cells, resulting in
enhanced responsivity to LPS.
Finally, we performed immunohistochemical staining with
anti-F4/80 and anti-p-STAT3 in Kupffer cells isolated from the
livers of chow- or HFD-fed WT mice to investigate whether
Kupffer cells in HFD-fed WT mice retain their responsivity to lep-
tin despite the mice exhibiting obesity (Figure S6Aii). As shown
in Figure S6C, leptin administration induced translocation of
pSTAT3 in the nuclei of Kupffer cells of HFD-fed WT mice as
well as those of chow-fed WT mice. These results suggest that
the intracellular signal transduction of leptin is retained even in
Kupffer cells isolated from HFD-fed WT mice.
Figure 6. CD14 Expression in RAW246.7 Cells, the Murine Mono-
cyte/Macrophage Cell Line, Is Induced by Leptin via STAT3
Signaling, Resulting in Hyperresponsivity to Low-Dose LPS
(A) Leptin-induced CD14 mRNA expression levels from RAW 264.7 cells in
a dose-dependent manner.
(B) Leptin alone or leptin with STAT3 inhibitor (S31-201)-induced CD14 mRNA
expression levels from RAW 264.7 cells.
(C) Leptin alone, leptin with lipopolysaccharide (LPS), or leptin with LPS and
STAT3 inhibitor-induced TNFa production obtained from RAW 264.7 cells.
These mRNA expression levels or production levels of the medium were as-
sessed 6 hr after the treatment. Results are presented as means ± SD.
Statistical significance was determined using ANOVA with Scheffe’s multiple
testing correction. (*p value < 0.05, **p value < 0.01).
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Serum Leptin Levels in Humans
To confirm the association between serum leptin levels and
hepatic CD14 expression in humans, we investigated serum
leptin levels and the mRNA levels of CD14 in liver samples
collected from patients with NAFLD, including nonalcoholic fatty
liver (NAFL) and NASH. Characteristics of these subjects are
shown in Table S4. Leptin levels and hepatic CD14 expression
in NAFL or NASH patients were much higher than those in
control subjects, and were similarly much higher in NASH than
those in NAFL. In addition, hepatic TNFa expression was
greater in NASH than those in NAFL, but not between NAFL
and control subjects (Figures 7A, 7B, and 7C). Interestingly,
serum leptin levels and hepatic CD14 expression were positively
correlated in control subjects and in NAFLD patients (r =
0.628, P<0.01; Figure 7D). Furthermore, we compared hepatic
CD14 expression between six overweight control subjects with
BMI > 25 kg/m2 but without NAFLD or hyperleptinemia and eight
patients with NASH accompaniedwith hyperleptinemiamatched
for BMI (Figures S7A and S7B). We found that hepatic CD14
mRNA levels were significantly higher in patients with NASH
than in BMI-matched overweight control subjects (Figure S7C).
These results suggest that increased leptin levels may be asso-
ciated with an increase in hepatic CD14 expression, leading to
increased responsivity to low-level endotoxin; in turn, this results
in liver inflammation via increased hepatic TNFa expression.DISCUSSION
In this study, we showed that leptin induces CD14 expression
via activation of STAT3 signaling in Kupffer cells, resulting in
enhanced responsivity against low-dose bacterial LPS in the
liver; in turn, this results in hepatic inflammation and fibrosis
(see Graphical Abstract). This is the first report to demonstrate
that leptin plays a critical role in the pathogenesis of nonalcoholic
steatohepatitis by enhancing responsivity to low-dose bacterial
endotoxin.
Previous studies have shown that gut-derived bacterial endo-
toxin may play a role in the progression of disease from simple
steatosis to steatohepatitis in NASH (Chitturi and Farrell, 2001;
Harte et al., 2010; Kudo et al., 2009; Miele et al., 2009; Shanab
et al., 2011; Zhao et al., 2004). Thus, we hypothesized that re-
sponsivity against gut-derived bacterial endotoxin might be
enhanced under simple steatosis compared with that of the
healthy liver. In fact, our data show that responsivity against
low-dose LPS was enhanced in HFD-induced murine steatosis
and that low-dose LPS led to liver injury and severe hepatic
fibrosis in HFD-fed mice, but not in chow-fed mice. We investi-
gated the mechanisms for enhancing responsivity against low-
dose LPS in HFD-induced murine steatosis compared with that
in chow-fed murine healthy liver, and revealed that CD14 is
overexpressed in the liver of HFD-fed WT mice in comparison
to chow-fed WT mice. Our present data clearly indicate that
CD14-positive cells are identified as Kupffer cells but not other
cells, and that an increase in CD14-positive Kupffer cells
contributes to enhanced responsivity against low-dose LPS in
simple steatosis; this suggests that hyperresponsivity against
low-dose bacterial endotoxin is regulated by the expression of
CD14 in Kupffer cells during simple steatosis. CD14 is an
important regulatory factor in the expression of an inflammatory
response to LPS and enhances the effect of LPS considerably in
Kupffer cells (Roncon-Albuquerque et al., 2008; Delude et al.,
1995; Ferrero et al., 1993; Haziot et al., 1995; Su, 2002; Wright
et al., 1990). In addition, a previous report showed that promoter
polymorphism of CD14 is a risk factor for human NASH (Brun
et al., 2006). Therefore, increased expression of CD14 is closely
related to the pathogenesis of NASH. In fact, our data showed
that CD14 mRNA expression levels are much higher in NAFLD
patients including NAFL and NASH than those in control
subjects. These results demonstrate that hepatic CD14 may be
an important factor in the development of NASH by enhancing
the hepatic inflammatory response against gut-derived bacterial
endotoxin.
We also investigated leptin-dependent increase in hepatic
CD14 expression using leptin-deficient ob/ob mice and leptin
receptor-deficient db/db mice. We found that both leptin-defi-
ciency and leptin receptor-deficiency led to a decrease in
hepatic CD14 expression, resulting in the decrease in responsiv-
ity to LPS, despite exhibiting severe obesity and steatosis. In
contrast to these findings, HFD-fed WT mice exhibited severe
obesity and steatosis with increases in hepatic CD14 expression
via increased serum leptin levels and activation of ObRb and
STAT3 signaling in the liver, leading to enhancing responsivity
to LPS. Furthermore, exogenously administered leptin in
chow-fed WT mice caused overexpression of hepatic CD14
despite a lack of obesity and steatosis, resulting in enhancingCell Metabolism 16, 44–54, July 3, 2012 ª2012 Elsevier Inc. 51
Figure 7. Serum Leptin Levels Are Positively
Correlated with Hepatic CD14 Expression Levels
in Humans
(A–D) Control subjects (n=25), NAFL patients (n=35),
NASH patients (n=57). (A) Hepatic CD14 and (B) TNFa
mRNA expression levels and (C) serum leptin levels in
NAFLD patients including NAFL and NASH, and control
subjects. Results are presented as means ± SD. Statistical
significance was determined using ANOVA with Scheffe’s
multiple testing correction (*p value < 0.05). (D) The
correlation between serum leptin levels and hepatic CD14
mRNA expression levels in humans (control subjects and
NAFLD patients) is shown. The correlation between serum
leptin levels and hepatic CD14 mRNA expression was
examined by regression analysis and determination of
standardized correlation coefficients. A P- value of < 0.05
was considered significant.
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observed in RAW246.7 and Kupffer cells isolated from chow-
fed WT mice treated with leptin in vitro. In addition, the increase
in CD14 expression in RAW246.7 was decreased after adminis-
tration of STAT3 inhibitor. These results suggest that leptin and
STAT3 signaling may increase responsivity to gut-derived, low-
dose bacterial endotoxin even in the healthy liver via an increase
in CD14-positive Kupffer cells, irrespective of steatosis.
In humans, increased serum leptin levels are generally associ-
ated with obesity, visceral fat accumulation, and steatosis
(Considine et al., 1996; Halaas et al., 1995), and patients with
NAFLD generally represent obesity and hyperleptinemia, except
in atypical cases such as lipodystrophy (Javor et al., 2005). In this
study, we observed that serum leptin levels and hepatic CD14
expression levels in patients with NAFLD were much higher
than those in control subjects, and similarly, these levels in
NASH patients were much higher than those in NAFL patients.
Significantly positive correlations between the serum leptin
levels and hepatic CD14 expression levels were observed. These
results clearly indicate that serum leptin levels and hepatic CD14
expression are closely associated with the onset of NAFL and
its progression to NASH. Namely, leptin-induced hepatic CD14
expression may enhance hepatic responsivity to gut-derived
bacterial endotoxins, even at low levels, resulting in the progres-
sion from NAFL to NASH. In general, NAFL is considered to be
progressed to NASH when several factors such as oxidative
stress, proinflammatory cytokines and gut-derived high-level
endotoxin are added to the conditions enhancing responsivity
to endotoxin via increase in hepatic CD14 expression. Under
these circumstances, hepatic TNFa expression may play an
important role in liver inflammation and fibrosis. Certainly, we
observed that hepatic TNFa expression was greater in NASH
than in NAFL, but not between NAFL and control subjects, indi-52 Cell Metabolism 16, 44–54, July 3, 2012 ª2012 Elsevier Inc.cating the important role of increased hepatic
CD14 expression in the progression of liver
damage from NAFL to NASH. Although there is
the limitation for a large scale analysis of liver
biopsies from BMI-matched overweight control
subjects, we found that hepatic CD14 mRNA
levels were significantly higher in patients with
NASH than in BMI-matched overweight controlsubjects. These results indicate that the increased expression
of hepatic CD14 levels are closely related to serum leptin levels.
We also showed that leptin receptor (ObR) was expressed in
Kupffer cells. Our results suggest that ObR-STAT3 signaling is
required for the expression of hepatic CD14 in Kupffer cells
and regulates responsivity to low-dose LPS. However, we found
that ObR was partially expressed in CD146-positive cells, which
are identified as sinusoidal endothelial cells (Figures S3F and
S3G). Namely, leptin may act with sinusoidal endothelial cells
directly. As shown in Figure S3D, however, we confirmed that
CD14 was not expressed in sinusoidal endothelial cells. These
results indicate that the leptin receptor of sinusoidal endothelial
cells does not seem to affect responsivity to LPS via increased
CD14 expression. Taken together, these data provide strong
evidence to indicate that leptin regulates responsivity against
low levels of bacterial endotoxin through the regulation of
hepatic CD14 expression via activation of STAT3 signaling in
Kupffer cells.
Due to the heterogeneous nature of NAFLD, it is unlikely that
NASH pathogenesis is dependent upon any one single factor.
Currently, the two-hit or multiple-parallel-hits theory is generally
accepted as pathogenesis of NAFLD (Day and James, 1998; Tilg
and Moschen, 2010). Our present study clearly indicated that a
gut-derived bacterial endotoxin-induced inflammation cascade,
activated by leptin-mediated CD14 expression in Kupffer cells,
is likely to be an important contributing factor for the pathogen-
esis and progression of NAFLD. Further research is required to
clarify the exact contributions of these pathways during NASH
progression.
In summary, we have shown that significantly increased
leptin induces overexpression of CD14 via activation of STAT3
signaling in Kupffer cells, resulting in a hepatic hyper-inflamma-
tory response to gut-derived low-dose bacterial endotoxin and
Cell Metabolism
The Role of Leptin in NASHprogression from simple steatosis to steatohepatitis with associ-
ated liver inflammation and fibrosis. These results propose
a therapeutic approach for NASH by targeting leptin-dependent
STAT3 and CD14 signaling.
EXPERIMENTAL PROCEDURES
Animal Experiments
Eight-week-old male C57BL/6J mice (Wild-type; WT), C57BL/6J-ob/ob mice,
C57BL/KsJ-db/+ mice, and C57BL/KsJ-db/db mice (n = 2–6 per group) were
purchased from CLEA Japan, Inc. We prepared a normal chow containing
22% protein, 6% fat, and 47% carbohydrate, as well as a high-fat diet (HFD)
containing 20% protein, 60% fat, and 20% carbohydrate. Experimental proto-
cols were performed as outlined in Figure S1. Animal protocols were approved
by the Yokohama City University Medical School Guidelines for the Care and
Use of Laboratory Animals.
In this study, LPS (E. coli, Sigma Chemical, St. Louis, MO; 0.25 mg/kg),
murine recombinant leptin (Peprotech, Rocky Hill, NJ; 5 mg/g), murine leptin
triple antagonist (ProSpec-Tany TechnoGene, Rehovot, Israel; 1-100 nM),
and STAT3 inhibitor (S31-201) (Santa Cruz Biotechnology, Inc, Santa Cruz,
CA; 50 mg/body) in 200 mL of 5% DMSO were used.
Cell Culture
The murine monocyte/macrophage cell line RAW264.7 was obtained from
ATCC (Rockville, MD). Cells were cultured at 37 CC under 5% CO2 in Dulbec-
co’s modified Eagle’s medium (ASAHI TECHNO GLASS Co., Tokyo, Japan),
and supplemented with 100 units/mL penicillin and 100 mg/mL streptomycin
plus 10% fetal bovine serum. After incubation, the medium was treated with
murine recombinant leptin (1, 10, 50, or 100 nM); LPS (10 ng/mL); and
STAT3 inhibitor (S31-201) (50mM) in DMSO. The final concentration of
DMSO in the medium was 1%.
Human Subjects
Fasted human blood was collected from a total of 117 patients (51.3 ± 17.4
years, 76 males) with biopsy-proven NAFLD and 25 healthy controls (39.5±
14.9 years, 19 males). The specimens of healthy controls were obtained
from the subjects who did not present liver inflammation and fibrosis. The
sub-categories of NAFLD were determined by liver biopsies and liver function
tests, by ballooning, and/or fibrosis in accordance with the proposals set out
by Brunt et al (Brunt et al., 1999; Kleiner et al., 2005) (Tables S5 and S6). The
subjects were divided into 3 categories: control subjects (control, n=25);
nonalcoholic fatty liver (NAFL, n = 35); and steatohepatitis (NASH, n = 57). In
a subgroup of 25 nondiabetic patients with NAFLD, various anthropometric
and biochemical parameters were assessed at baseline. The study was
approved by the Ethics Research Committee of Yokohama City University,
and written agreements were obtained from all participants after informed
consent.
Biochemistry
Serum ALT, leptin, glucose, and insulin serum concentrations were measured
by a local laboratory for clinical examinations (SRL Co, Ltd, Tokyo, Japan). As
an alternative method for assessing insulin resistance (IR), the homeostasis
model assessment of IR (HOMA-IR) was calculated using the following
formula: fasting insulin (mU/mL) 3 plasma glucose (mg/dL) / 405.
Liver Histology
Paraffin-embedded sections were stained with hematoxylin and eosin staining
(HE staining), Masson’s trichrome staining (MT staining), or Sirius red staining
(SR staining). NAFLD activity score (NAS) and fibrosis stage were scored inde-
pendently by two experienced pathologists blinded to the experimental proce-
dures and the results of clinical data, according to the criteria (Brunt et al.,
1999; Kleiner et al., 2005) outlined in Tables S4 and S5.
Immunohistochemistry, Immunofluorescence, and Immunoblotting
Immunohistochemistry was performed on 7 mm cryostat liver sections. The
sections were incubated with primary antibodies and stained with Alexa Flu-
oro-conjugated secondary antibodies (Cell Signaling Technology, Inc, Japan).Proteins were incubated with primary antibodies, and HRP-conjugated
secondary antibody (Cell Signaling Technology). The primary antibodies
used were shown in Supplemental Experimental Procedures.
RNA Isolation and Real-Time PCR Analysis
Total RNA was extracted from liver tissue samples using the RNeasy mini
kit (QIAGEN, Tokyo, Japan). Messenger RNA (mRNA) of murine or human
TLR4, CD14, F4/80, TNFa, IL-6, and b-actin were determined in liver tissue
using fluorescence-based RT-PCR and an ABI PRISM 7700 Sequence Detec-
tion System (Life Technologies, Carlsbad, CA).
Preparations of Small Interfering RNAs
Weprepared synthetic small interfering RNAs (siRNAs) from Takara Bio (Shiga,
Japan) targeted to CD14. Sequences of the sense and antisense strands of
siRNAs were: forward 50-AGUUCAGAGACAGGAAUAA-30, reverse 30-UAUC
AAGUCUCUGUCCUUAUU-50. Synthetic CD14 siRNAs were delivered in vivo
using a modified hydrodynamic transfection method (Yeikilis et al., 2006).
Statistical Analysis
Data are presented as means ± SD. Differences between the two groups were
assessed using the unpaired two-tailed Student’s t-test. Data sets involving
more than two groups were assessed by ANOVA with Scheffe’s multiple
testing correction. The relationship between serum leptin levels and hepatic
CD14 expression in humans was examined by regression analysis and deter-
mination of standardized correlation coefficients. A p value of < 0.05 was
considered significant. All statistical analyses were performed using StatView
version 5.0 software (SAS Institute Japan Ltd., Tokyo, Japan).
Abbreviations
ALT, alanine aminotransferase; a-SMA, a-smooth muscle actin; GdCl3, gado-
linium chloride; HFD, high-fat diet; HOMA-IR, homeostasis model assessment
for insulin resistance; IL-6, Interleukin-6; IR, insulin resistance; LPS, lipopoly-
saccharide; MT staining, Masson’s trichrome staining; NAFL, nonalcoholic
fatty liver; NAFLD, nonalcoholic fatty liver disease; NAS, NAFLD activity score;
NASH, nonalcoholic steatohepatitis; RNAi, RNA interference; siRNA, small
interfering RNA; SR staining, Sirius red staining; STAT3, signal transducer
and activator of transcription 3; TG, triglycerides; TLR4, Toll like receptor 4;
TNFa, tumor necrosis factor alpha; WT, wild type.
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